| scholarly article | Q13442814 |
| P2093 | author name string | Richard Dalby | |
| Varsha Chavan | |||
| P2860 | cites work | Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth | Q24295049 |
| Structure and expression of human fibroblast growth factor-10 | Q28248300 | ||
| Characterization of recombinant human fibroblast growth factor (FGF)-10 reveals functional similarities with keratinocyte growth factor (FGF-7) | Q28270502 | ||
| The roles of FGFs in the early development of vertebrate limbs | Q28273288 | ||
| Fgf10 is essential for limb and lung formation | Q28295033 | ||
| Mouse fibroblast growth factor 10: cDNA cloning, protein characterization, and regulation of mRNA expression | Q28512553 | ||
| Fibroblast growth factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lung | Q28594241 | ||
| Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins | Q31135530 | ||
| Keratinocyte growth factor-2 (FGF-10) promotes healing of experimental small intestinal ulceration in rats | Q31503184 | ||
| Functions of fibroblast growth factors in vertebrate development | Q40918251 | ||
| Receptor-mediated endocytosis of keratinocyte growth factor. | Q42824764 | ||
| Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. | Q43706400 | ||
| Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor | Q48059051 | ||
| Structure and expression of the rat mRNA encoding a novel member of the fibroblast growth factor family | Q48062267 | ||
| Renal hemodynamics and prostaglandin E2 excretion in a nonhuman primate model of septic shock | Q68925323 | ||
| Efficacy of keratinocyte growth factor-2 in dextran sulfate sodium-induced murine colitis | Q77921631 | ||
| In vivo characterization of keratinocyte growth factor-2 as a potential wound healing agent | Q78032745 | ||
| P433 | issue | 2 | |
| P304 | page(s) | E6 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | AAPS PharmSci | Q26839729 |
| P1476 | title | Novel system to investigate the effects of inhaled volume and rates of rise in simulated inspiratory air flow on fine particle output from a dry powder inhaler | |
| P478 | volume | 4 |
| Q51001143 | Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization. |
| Q34265177 | Developing ways to evaluate in the laboratory how inhalation devices will be used by patients and care-givers: the need for clinically appropriate testing |
| Q35609773 | Dry powder inhalers for optimal drug delivery |
| Q38126940 | Improved laboratory test methods for orally inhaled products |
| Q46678370 | Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses |
| Q33266966 | Influence of realistic inspiratory flow profiles on fine particle fractions of dry powder aerosol formulations |
| Q42971090 | Inhalation performance of physically mixed dry powders evaluated with a simple simulator for human inspiratory flow patterns |
| Q36703845 | Metabolic drug interactions with newer antipsychotics: a comparative review. |
| Q43152667 | The abbreviated impactor measurement (AIM) concept: part II--Influence of evaporation of a volatile component-evaluation with a "droplet-producing" pressurized metered dose inhaler (pMDI)-based formulation containing ethanol as cosolvent |
Search more.